Remote Ischemic Conditioning for Cerebral Ischemia in Patients With

Status Not yet recruiting

Clinical Trial Summary

The aim of this study is to evaluate the safety and efficacy of remote ischemic conditioning ( RIC ) in the protection of cerebral ischemia in patients with Takayasu arteritis ( TAK ). The study was designed as a prospective, double-blind, exploratory randomized controlled study. The entire study included a screening period and a treatment observation period ( a total of 24 weeks ). All patients with cerebral ischemia of TAK will be randomly divided into RIC group and sham RIC group at 1:1 ratio. On the basis of receiving the conventional drug therapy, the patients will be treated with RIC or sham RIC treatment twice daily for six month. The clinical data of patients at baseline and each follow-up will be collected, including basic information, disease activity assessment, laboratory indicators, imaging indicators, treatment data, adverse events, etc.The Primary outcome is the mean cerebral blood flow improvement rate ( mCBF-IR ) of TAK patients after 24 weeks-treatment. Secondary endpoints include the incidence of major adverse cerebrovascular events ( MACE ) , the change value of arterial transit time ( ATT ) in pCASL hypoperfusion area compared with baseline, occurrence of RIC-related adverse reactions, the changes of hematological indexes and disease activity score, etc. This study will provide insights into the preliminary proof of principle, safety, and efficacy of RIC in cerebral ischemia in patients with Takayasu arteritis ( TAK ), and this data will provide parameters for future larger scale clinical trials if efficacious.

Clinical Trial Description

Clinical symptoms, routine follow-up laboratory tests, other serological indicators (VEGF, NGF, ET-1, ACE), PAF, PDGF, etc.), vascular involvement, cranial MRI, vascular injury score, disease activity and treatment will be collected at baseline. After RIC or sham RIC intervention, clinical symptoms, laboratory tests, disease activity, treatment and RIC-related adverse reactions will be collected at 1m, 2m,3m and 6m. the data of vascular involvement, cranial MRI, vascular injury score and disease activity will also be collected at 6 months follow-up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06178419
Study type	Interventional
Source	Xuanwu Hospital, Beijing
Contact	Yi Zhao, MD
Phone	+8613811038669
Email	zy85070@xwhosp.org
Status	Not yet recruiting
Phase	N/A
Start date	January 1, 2024
Completion date	July 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT04167527` - Endovascular Therapy for Low NIHSS Ischemic Strokes	Phase 2/Phase 3
Recruiting	`NCT04583163` - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Completed	`NCT01436812` - Effect of Positive End Expiratory Pressure (PEEP) on Cerebral Oxymetry During Laparoscopy	N/A
Terminated	`NCT00141011` - Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke	Phase 3
Recruiting	`NCT05053932` - Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia
Completed	`NCT04437862` - A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke	N/A
Completed	`NCT00598819` - A Prospective Study of a New Device for Monitoring Cerebral Oxygenation on Healthy Volunteers	Phase 1
Completed	`NCT00207961` - The Threshold Value of Regional Cerebral Oxygenation in Detecting Cerebral Ischemia	N/A
Not yet recruiting	`NCT04696523` - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage	Phase 2
Completed	`NCT02351518` - Cerebral Autoregulation and Vasospasm in Patients With TBI
Completed	`NCT01546636` - The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position	N/A
Completed	`NCT04047563` - Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke	Phase 3
Completed	`NCT05087836` - Correlation of Cerebral Oxygen Saturation Measured From 2 Sensor Sites: Forehead vs. Temporal
Completed	`NCT02448069` - Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke	Phase 2
Completed	`NCT02147275` - Monitoring Hypertensive Patients's Cerebral Oxygen Saturation	N/A
Completed	`NCT01875055` - Reversing Cerebral Oxygen Desaturations Greater That 10% of Baseline Values Using NIRS in the ICU	N/A
Completed	`NCT02389647` - Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury
Completed	`NCT02643030` - Hypercapnia During Shoulder Arthroscopy	N/A
Completed	`NCT01436799` - Desflurane Versus Propofol in the Sitting Position	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1) — TARIC-1

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms